SEATTLE, May 10, 2021, (MEDGADGET) — Overview:
Seasonal affective disorder (SAD) has been identified and included in the diagnostic classification system of the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, as a major depressive disorder with seasonal pattern. Seasonality, means that climate change is having a profound effect on people all over the world. Moreover, increasing incidence of seasonal affective disorder is expected to boost the global seasonal affective disorder market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that around 14% of the adult in the U.S. population suffers from a lesser form of seasonal mood changes, known as winter blues.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4333
The global seasonal affective disorder market is estimated to be valued at US$ 544.7 million in 2020 and is expected to exhibit a CAGR of 5.5% during the forecast period (2020-2027).
Global Seasonal Affective Disorder Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus epidemic (COVID-19) and the lockdowns of various countries around the world have had an impact on the financial situation of businesses in all sectors. Private healthcare is one such sector, most affected by the COVID-19 epidemic.
The lockdown in various countries due to the epidemic has put an economic burden on the healthcare sector. However, the coronavirus epidemic has disrupted the development, production, and supply of drugs and other health products and has affected the growth of health care businesses in various companies around the world.
As a result, the impact of the COVID-19 epidemic is also expected to limit the growth of the global seasonal affective disorder market during the forecast period.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4333
Rising cases of seasonal affective disorder is expected to drive growth of the global seasonal affective disorder market.
Increasing cases of seasonal affective disorder is expected to propel growth of the global seasonal affective disorder market over the forecast period. For instance, according to an article published by the Royal College of Psychiatrists, in April 2015, reports that around 3 out of 100 people had significant winter depressions in the U.K.
Rising cases of seasonal affective disorder (SAD) in North America is expected to boost global seasonal affective disorder market growth.
North America is expected to hold a high position in the global seasonal affective disorder market, due to an increase in the number of the seasonal affective disorder (SAD) in the region. For instance, according to an article published by the Boston University, in October 2019, reports that 10 million U.S. populace are affected by seasonal affective disorder, with women 4 times more likely to be diagnosed than men.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/seasonal-affective-disorder-market-3593
Side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the global seasonal affective disorder market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as ophthalmologic including blurred vision; central nervous system including insomnia, headache, agitation, dizziness; dermatologic such as diaphoresis, and others.
- By Type: Fall & Winter Seasonal Affective Disorder, Spring & Summer Seasonal Affective Disorder, Others.
- By Treatment: Light Therapy, Medications, Psychotherapy, Counselling, Others.
- By End User: Hospitals, Clinics, Research Institutes, Others.
Some of the key players operating in the global seasonal affective disorder market such as Pfizer, Inc., Johnson & Johnson Services Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi, AbbVie Inc., Eli Lily and Company, Novartis AG, Mylan, Inc., F. Hoffmann-La Roche AG, Bausch Health, Allergan, Koninklijke Philips N.V., Bristol-Myers Squibb, Bayer AG, and Henry Schein Inc., among others.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027